|August 8, 2014|
|08:17 EDT||PCYC||Pharmacyclics announces Jesse McGreivy to step down from Chief Medical Officer|
McGreivy will transition to senior advisor of the company, and will provide advisory services to the company for up to six months. McGreivy initiated the transition for personal reasons
News For PCYC From The Last 14 Days
|May 26, 2015|
|09:03 EDT||PCYC||Rosetta announces selection of first pilot project grant under MCC alliance|
Rosetta Genomics (ROSG) announces the selection of the first project grant under its strategic alliance with Moffitt Cancer Center. The funded project is titled, “miRNAs as Determinants and Predictors of Ibrutinib Resistance in Mantle Cell Lymphoma.” The project will be led by Jianguo Tao, M.D., Ph.D., a renowned hematopathologist and physician-scientist at the Molecular and Chemical Biology Program at Moffitt, and Bijal Shah, M.D., an oncologist in the Experimental Therapeutic Program at Moffitt. MCL is an aggressive B-cell lymphoma. Ibrutinib, a blockbuster pharmaceutical marketed by Pharmacyclics (PCYC) under the brand name of IMBRUVICA, is a novel Bruton's tyrosine kinase inhibitor that received U.S. Food and Drug Administration approval for the treatment of MCL in 2014, with high response rates reported in patients with MCL. However, many MCL patients who initially show a partial or complete response to ibrutinib, eventually develop ibrutinib-acquired drug resistance accompanied by fulminant progression and accelerated mortality. Studies conducted by Drs. Tao and Shah have suggested that microRNAs play a role in the development of resistance to ibrutinib. The goal of this funded project is to further explore the role and underlying molecular mechanism of microRNAs in ibrutinib resistance in MCL, for development of microRNA-based predictive biomarkers for ibrutinib therapy, as well as for a rational design to overcome drug resistance.
|08:32 EDT||PCYC||AbbVie completes acquisition of Pharmacyclics |
Subscribe for More Information
|May 22, 2015|
|08:06 EDT||PCYC||Pharmacyclics announces positive opinion from EMA for Imbruvica|
Subscribe for More Information
|08:00 EDT||PCYC||AbbVie announces expiration of HSR waiting period for Pharmacyclics acquisition|
AbbVie (ABBV) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for AbbVie's purchase of Pharmacyclics (PCYC) has expired today. The expiration satisfies the exchange offer condition with respect to the approvals and clearances required under antitrust laws. Assuming that the other customary exchange offer conditions are satisfied, including a minimum tender of at least a majority of outstanding Pharmacyclics shares, it is expected that the exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics will expire today at 5:00 p.m., New York City time, without any further extension.
|May 21, 2015|
|08:04 EDT||PCYC||AbbVie announces offer consideration for acquisition of Pharmacyclics |
AbbVie (ABBV) announced the per share offer consideration amounts pursuant to its previously announced offer to acquire each outstanding share of common stock of Pharmacyclics (PCYC) for a mix of cash and AbbVie common stock, as described in the Registration Statement on Form S-4 filed with the SEC by AbbVie on March 23, 2015, as amended. The mixed consideration will consist of $152.25 in cash and 1.6639 shares of AbbVie common stock and, subject to proration, the all-stock consideration will consist of 3.9879 shares of AbbVie common stock.
|May 20, 2015|
|09:07 EDT||PCYC||Johnson & Johnson says exploring eight new indications for Imbruvica|
Imbruvica is jointly developed and commercialized by Pharmacyclics (PCYC) and Johnson & Johnson (JNJ) subsidiary Janssen Biotech. AbbVie (ABBV) is in the process of acquiring Pharmacyclics.
|May 15, 2015|
|16:46 EDT||PCYC||AbbVie extends exchange offer to acquire Pharmacyclics|
AbbVie (ABBV) announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics (PCYC) to 5 p.m., New York City time, on May 22. The depositary of the exchange offer has advised that, as of 4:00 p.m., New York City time, on May 15, a total of approximately 42,822,941 shares of Pharmacyclics common stock were validly tendered and not properly withdrawn in the exchange offer. All other terms and conditions of the exchange offer remain unchanged.
|May 13, 2015|
|17:50 EDT||PCYC||Pharmacyclics to showcase new 'promising' Imbruvica data at ASCO|
Pharmacyclics announced that ibrutinib, also known as Imbruvica, single-agent and combination data will be featured in seven oral and poster sessions at the 51st American Society of Clinical Oncology, ASCO, Annual Meeting being held May 29-June 2 in Chicago, IL. According to a statement from ASCO, Imbruvica data will also be included in the official press program during the meeting for the second time in two years. Imbruvica is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a Johnson & Johnson (JNJ) subsidiary. Data being presented include, among others, an oral presentation from the Phase III HELIOS study of ibrutinib in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia, a poster presentation of ibrutinib in steroid-dependent or refractory chronic graft-versus-host-disease as well as a dose adherence analysis of ibrutinib 420 mg administered to previously treated CLL patients. "We look forward to sharing promising data at this year's ASCO that examines the use of Imbruvica across a broad range of hematologic disease settings from our clinical studies," said Danelle James, M.D., M.S., Head of Oncology at Pharmacyclics.